Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort
Authors
Keywords
-
Journal
BRITISH JOURNAL OF CANCER
Volume 113, Issue 7, Pages 989-995
Publisher
Springer Nature
Online
2015-09-16
DOI
10.1038/bjc.2015.328
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- O-0003 * NAPOLI-1: RANDOMIZED PHASE 3 STUDY OF MM-398 (NAL-IRI), WITH OR WITHOUT 5-FLUOROURACIL AND LEUCOVORIN, VERSUS 5-FLUOROURACIL AND LEUCOVORIN, IN METASTATIC PANCREATIC CANCER PROGRESSED ON OR FOLLOWING GEMCITABINE-BASED THERAPY
- (2014) D. Von Hoff et al. ANNALS OF ONCOLOGY
- FOLFOX as second-line chemotherapy in patients with pretreated metastatic pancreatic cancer from the FIRGEM study
- (2014) Aziz Zaanan et al. BMC CANCER
- A phase II study of capecitabine plus docetaxel in gemcitabine-pretreated metastatic pancreatic cancer patients: CapTere
- (2014) Heloisa P. Soares et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- 5-Fluorouracil/Leucovorin Combined with Irinotecan and Oxaliplatin (FOLFIRINOX) as Second-Line Chemotherapy in Patients with Advanced Pancreatic Cancer Who Have Progressed on Gemcitabine-Based Therapy
- (2014) Min Geun Lee et al. CHEMOTHERAPY
- Guidelines for time-to-event end-point definitions in trials for pancreatic cancer. Results of the DATECAN initiative (Definition for the Assessment of Time-to-event End-points in CANcer trials)
- (2014) Franck Bonnetain et al. EUROPEAN JOURNAL OF CANCER
- Second-Line Oxaliplatin, Folinic Acid, and Fluorouracil Versus Folinic Acid and Fluorouracil Alone for Gemcitabine-Refractory Pancreatic Cancer: Outcomes From the CONKO-003 Trial
- (2014) Helmut Oettle et al. JOURNAL OF CLINICAL ONCOLOGY
- Sustained response with gemcitabine plus Nab-paclitaxel after folfirinox failure in metastatic pancreatic cancer: Report of an effective new strategy
- (2014) Alix Portal et al. Clinics and Research in Hepatology and Gastroenterology
- Second-line treatment in advanced pancreatic cancer: a comprehensive analysis of published clinical trials
- (2013) O. E. Rahma et al. ANNALS OF ONCOLOGY
- Transformation and additional malignancies are leading risk factors for an adverse course of disease in marginal zone lymphoma
- (2013) A. H. Meyer et al. ANNALS OF ONCOLOGY
- Use of Statins and the Risk of Death in Patients With Prostate Cancer
- (2013) Oriana Yu et al. JOURNAL OF CLINICAL ONCOLOGY
- Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
- (2013) Daniel D. Von Hoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Phase II Trial of nab-Paclitaxel as Second-line Therapy in Patients With Advanced Pancreatic Cancer
- (2012) Peter J. Hosein et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- Cancer statistics, 2012
- (2012) Rebecca Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Levels of Gemcitabine Transport and Metabolism Proteins Predict Survival Times of Patients Treated With Gemcitabine for Pancreatic Adenocarcinoma
- (2012) Raphaël Maréchal et al. GASTROENTEROLOGY
- Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: A phase III-study from the German CONKO-study group
- (2011) Uwe Pelzer et al. EUROPEAN JOURNAL OF CANCER
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
- (2011) Thierry Conroy et al. NEW ENGLAND JOURNAL OF MEDICINE
- 5-Fluorouracil/Leucovorin Combined with Irinotecan and Oxaliplatin (FOLFIRINOX) as Second-Line Chemotherapy in Patients with Metastatic Pancreatic Adenocarcinoma
- (2011) Elias Assaf et al. ONCOLOGY
- Combination 5-fluorouracil, folinic acid and cisplatin (LV5FU2-CDDP) followed by gemcitabine or the reverse sequence in metastatic pancreatic cancer: final results of a randomised strategic phase III trial (FFCD 0301)
- (2010) L. Dahan et al. GUT
- Pancreatic Cancer
- (2010) Manuel Hidalgo NEW ENGLAND JOURNAL OF MEDICINE
- A randomised phase II study of modified FOLFIRI.3 vs modified FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancer
- (2009) C Yoo et al. BRITISH JOURNAL OF CANCER
- EUROCARE-4. Survival of cancer patients diagnosed in 1995–1999. Results and commentary
- (2009) Milena Sant et al. EUROPEAN JOURNAL OF CANCER
- Second- and third-line chemotherapy in patients with metastatic pancreatic adenocarcinoma: Feasibility and potential benefits in a retrospective series of 117 patients
- (2009) J.-B. Bachet et al. GASTROENTEROLOGIE CLINIQUE ET BIOLOGIQUE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More